Caligan Partners
Latest statistics and disclosures from Caligan Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LQDA, VRNA, EXEL, EOLS, ANIK, and represent 72.53% of Caligan Partners's stock portfolio.
- Added to shares of these 9 stocks: SAGE (+$17M), MRUS (+$11M), EOLS (+$5.5M), ABVX (+$5.5M), VRCA (+$5.2M), YMAB, BCRX, AGIO, MLYS.
- Started 4 new stock positions in ABVX, VRCA, MRUS, SAGE.
- Reduced shares in these 3 stocks: IMAB, OTLK, ENTA.
- Sold out of its positions in IMAB, OTLK.
- Caligan Partners was a net buyer of stock by $46M.
- Caligan Partners has $395M in assets under management (AUM), dropping by 25.17%.
- Central Index Key (CIK): 0001727492
Tip: Access up to 7 years of quarterly data
Positions held by Caligan Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Caligan Partners
Caligan Partners holds 14 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 29.3 | $116M | 8.1M | 14.23 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 16.9 | $67M | 1.4M | 46.44 |
|
|
| Exelixis (EXEL) | 12.9 | $51M | 1.5M | 33.30 |
|
|
| Evolus (EOLS) | 7.5 | $30M | +22% | 2.7M | 11.04 |
|
| Anika Therapeutics (ANIK) | 6.0 | $24M | 1.4M | 16.46 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 5.7 | $23M | +15% | 3.0M | 7.52 |
|
| Agios Pharmaceuticals (AGIO) | 5.2 | $21M | +8% | 626k | 32.86 |
|
| Sage Therapeutics (SAGE) | 4.2 | $17M | NEW | 3.1M | 5.43 |
|
| Y Mabs Therapeutics (YMAB) | 3.5 | $14M | +47% | 1.8M | 7.83 |
|
| Mineralys Therapeutics (MLYS) | 3.2 | $12M | +3% | 1.0M | 12.31 |
|
| Merus N V (MRUS) | 2.7 | $11M | NEW | 255k | 42.05 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.4 | $5.5M | NEW | 752k | 7.32 |
|
| Verrica Pharmaceuticals (VRCA) | 1.3 | $5.2M | NEW | 7.4M | 0.70 |
|
| Enanta Pharmaceuticals (ENTA) | 0.3 | $1.1M | -42% | 185k | 5.75 |
|
Past Filings by Caligan Partners
SEC 13F filings are viewable for Caligan Partners going back to 2022
- Caligan Partners 2024 Q4 filed Feb. 14, 2025
- Caligan Partners 2024 Q3 filed Nov. 14, 2024
- Caligan Partners 2024 Q2 filed Aug. 14, 2024
- Caligan Partners 2024 Q1 filed May 13, 2024
- Caligan Partners 2023 Q4 filed Feb. 14, 2024
- Caligan Partners 2023 Q3 filed Nov. 14, 2023
- Caligan Partners 2023 Q2 filed Aug. 14, 2023
- Caligan Partners 2023 Q1 filed May 15, 2023
- Caligan Partners 2022 Q4 restated filed May 15, 2023
- Caligan Partners 2022 Q4 filed Feb. 15, 2023